Literature DB >> 16280683

How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease.

Mark R Cookson1, Georgia Xiromerisiou, Andrew Singleton.   

Abstract

PURPOSE OF REVIEW: Rapid progress in genetics has meant that there are now five genes identified for 'Parkinson's disease'. The detailed phenotypes vary, but generally the dominant genes cause a Lewy body disease spectrum whereas recessive genes cause a milder parkinsonism with variable inclusion body pathology. The subject of this review is to highlight these discoveries and to discuss their relationships to idiopathic Parkinson's disease. RECENT
FINDINGS: In January 2004, mutations in PINK1, coding for a mitochondrial kinase, were found to be causal for recessive parkinsonism. Subsequently, several studies have found additional mutations associated with early onset parkinsonism. Some cases have been described with a phenotype much closer to idiopathic Parkinson's disease, but it does not appear that PINK1 is a major risk factor for the sporadic disease. Later in the same year, the LRRK2 gene was shown to cause a dominant disease with a broader phenotype. The protein product was named dardarin and contains GTPase and kinase domains. Lewy bodies have been reported in LRRK2 cases, potentially linking this gene with sporadic Parkinson's disease. One mutation, G2019S, is found in a significant percentage of cases, including sporadic Parkinson's disease.
SUMMARY: Mutations in these two genes, along with previously described Mendelian variants, are beginning to yield important information about loss of specific neuronal groups or to protein inclusion pathology. How this relates to sporadic Parkinson's disease, however, is not yet fully defined. There are clear phenotypic overlaps with genetic and sporadic Parkinson's disease, especially for the dominant genes, suggesting that common facets of pathogenesis may exist.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280683     DOI: 10.1097/01.wco.0000186841.43505.e6

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  20 in total

Review 1.  Assessment of the progression of Parkinson's disease: a metabolic network approach.

Authors:  Thomas Eckert; Chengke Tang; David Eidelberg
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

2.  PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway.

Authors:  Ruth Mélida Sánchez-Mora; Humberto Arboleda; Gonzalo Arboleda
Journal:  J Mol Neurosci       Date:  2012-01-03       Impact factor: 3.444

Review 3.  Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.

Authors:  Bin Liu
Journal:  AAPS J       Date:  2006-09-29       Impact factor: 4.009

4.  The parkin mutant phenotype in the fly is largely rescued by metal-responsive transcription factor (MTF-1).

Authors:  Nidhi Saini; Oleg Georgiev; Walter Schaffner
Journal:  Mol Cell Biol       Date:  2011-03-07       Impact factor: 4.272

5.  The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration.

Authors:  Cherry Cheng-Ying Ho; Hardy J Rideout; Elena Ribe; Carol M Troy; William T Dauer
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

Review 6.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

7.  Genetic neuropathology of Parkinson's disease.

Authors:  Mark R Cookson; John Hardy; Patrick A Lewis
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

8.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

9.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.

Authors:  Junpeng Deng; Patrick A Lewis; Elisa Greggio; Eli Sluch; Alexandra Beilina; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

10.  Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration.

Authors:  Hui-Ming Gao; Paul T Kotzbauer; Kunihiro Uryu; Susan Leight; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2008-07-23       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.